[HTML][HTML] The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are
being rolled out under emergency use authorizations. It is of great concern that newly …
being rolled out under emergency use authorizations. It is of great concern that newly …
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection
Effective therapies are urgently needed for the SARS-CoV-2/COVID-19 pandemic. We
identified panels of fully human monoclonal antibodies (mAbs) from large phage-displayed …
identified panels of fully human monoclonal antibodies (mAbs) from large phage-displayed …
[HTML][HTML] Human neutralizing antibodies elicited by SARS-CoV-2 infection
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that …
respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that …
Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B. 1.1. 529
The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …
1.1. 529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent …
Potently neutralizing and protective human antibodies against SARS-CoV-2
The ongoing pandemic of coronavirus disease 2019 (COVID-19), which is caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health …
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
L Wang, T Zhou, Y Zhang, ES Yang, CA Schramm… - Science, 2021 - science.org
INTRODUCTION Worldwide appearance of severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
2 (SARS-CoV-2) variants of concern (VOCs) with increased transmissibility and resistance to …
Antigenicity and receptor affinity of SARS-CoV-2 BA. 2.86 spike
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies
E Andreano, R Rappuoli - Nature medicine, 2021 - nature.com
SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies |
Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a …
Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a …